94 Chinese Studies Selected for ASCO 2026; Ivosidenib Advances to Main Session

GateNews
At the 2026 American Society of Clinical Oncology (ASCO) annual meeting, 94 Chinese research projects were selected as oral presentations, with Ivosidenib featured in the general session. According to a note by CITIC Securities, the development marks a milestone for Chinese innovative drugs' growing influence in global academic discourse.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments